Purchase this article with an account.
B.G. Haik, K.C. Alejandro, J.E. Cantrell, M.W. Wilson; Does the Rate of Regression of Large Melanomas of the Ciliary Body and/or Choroid Receiving 125I Episcleral Plaque Brachytherapy Predict the Likelihood of Metastases? . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1554.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To determine the rate of regression of large melanomas of the ciliary body and/or choroid receiving 125 I episcleral plaque brachytherapy and to compare these rates between those patients who did and did not develop metastases. Methods: We retrospectively reviewed charts to identify patients whose tumors at presentation measured greater than either 8 mm in apical height or 16 mm in maximal basal diameter on B-scan ultrasonography and who received 125I episcleral plaque brachytherapy. Tumor dimensions following treatment were recorded. Tumor volumes were approximated using the formula for an elliptical cone. A regression rate for each patient was then calculated. We used a paired t-test to compare the rate of tumor regression between those patients who developed metastases and those who did not. Results: One hundred twenty-four patients, aged 13 to 86 years, with large melanomas of the ciliary body and/or choroid were treated between January 1986 and April 2001. Median follow-up was 40 months. Tumors were controlled locally in 90% (n = 112) of patients; 19% (n = 22) developed metastases at a median of 24 months after treatment. The mean slope for those patients who developed metastases was -116 (range, -538 to 50.8), and for those who did not, -93.8 (range, -606 to 148). No statistical difference in the rate of regression was found between the 2 groups (p = 0.4399). Conclusions: In our study, the rate of regression of large melanomas of the ciliary body and/or choroid receiving 125I episcleral plaque brachytherapy did not predict which patients were more likely to develop metastases.
This PDF is available to Subscribers Only